Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,156)

Items 101–200 of 12,156

1. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
   Martín Cowie, Miles Fisher · 2020 · Nature Reviews Cardiology
2. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension.
   2019 · PubMed Central
3. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options
   Viviany R. Taqueti, Marcelo F. Di Carli · 2018 · Journal of the American College of Cardiology
4. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial
   Inzucchi, Silvio E., Zinman, Bernard, Fitchett, David, Wanner, Christoph, Ferrannini, Ele, Schumacher, Martin, Schmoor, Claudia, Ohneberg, Kristin, Johansen, Odd Erik, George, Jyothis T. et al. · 2018 · Diabetes Care
5. Metabolomics and Metabolic Diseases: Where Do We Stand?
   Christopher B. Newgard · 2016 · Cell Metabolism
6. 9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2019</i>
   American Diabetes Association · 2019 · Diabetes Care
7. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
   Gornik, Heather L., Aronow, Herbert D., Goodney, Philip P., Arya, Shipra, Brewster, Luke Packard, Byrd, Lori, Chandra, Venita, Drachman, Douglas E., Eaves, Jennifer M., Ehrman, Jonathan K. et al. · 2024 · Circulation
8. Obesity and cardiovascular disease: revisiting an old relationship
   Chrysi C. Koliaki, Stavros Liatis, Alexander D. Kokkinos · 2018 · Metabolism
9. The science of obesity management: an endocrine society scientific statement
   Bray, George A, Heisel, William E, Afshin, Ashkan, Jensen, Michael D, Dietz, William H, Long, Michael, Kushner, Robert F, Daniels, Stephen R, Wadden, Thomas A, Tsai, Adam G et al. · 2018 · Endocrine Reviews
10. Basic Mechanisms of Diabetic Heart Disease
    Rebecca Helen Ritchie, E. Dale Abel · 2020 · Circulation Research
11. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
    Lawrence Blonde, Kamlesh K. Khunti, Stewart B. Harris, Casey Meizinger, NEIL SKOLNIK · 2018 · Advances in Therapy
12. Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
    Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas Rudolf Pieber, Elza Muscelli · 2016 · Diabetes
13. Metabolic remodelling in heart failure
    Edoardo Bertero, Christoph Maack · 2018 · Nature Reviews Cardiology
14. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
    Sebastian Steven, Katie Frenis, Matthias Walter Oelze, Sanela Kalinovic, Marin Kuntić, María Teresa Bayo Jiménez, Ksenija Vujačić-Mirski, Johanna Helmstädter, Swenja Kröller‐Schön, Thomas F. Münzel et al. · 2019 · Oxidative Medicine and Cellular Longevity
15. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology
    Seferović, Petar M., Petrie, Mark C., Filippatos, Gerasimos S., Anker, Stefan D., Rosano, Giuseppe, Bauersachs, Johann, Paulus, Walter J., Komajda, Michel, Cosentino, Francesco, de Boer, Rudolf A. et al. · 2018 · European Journal of Heart Failure
16. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
    Margulies, Kenneth B., Hernandez, Adrian F., Redfield, Margaret M., Givertz, Michael M., Oliveira, Guilherme H., Cole, Robert, Mann, Douglas L., Whellan, David J., Kiernan, Michael S., Felker, G. Michael et al. · 2016 · JAMA
17. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure ― Digest Version ―
    Hiroyuki Tsutsui, Mitsuaki Isobe, Hiroshi Ito, Hiroshi Ito, Ken Okumura, Minoru Ōno, Masafumi Kitakaze, Koichiro Kinugawa, Yasuki Kihara, Yoichi Goto et al. · 2019 · Circulation Journal
18. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
    Yiwen Li, Yanfei Liu, Shiwei Liu, Mengqi Gao, Wenting Wang, Keji Chen, Luqi Huang, Yue Liu · 2023 · Signal Transduction and Targeted Therapy
19. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    2016 · New England Journal of Medicine
20. Targeting adipose tissue in the treatment of obesity-associated diabetes
    Kusminski, Christine M., Bickel, Perry E., Scherer, Philipp E. · 2016 · Nature Reviews Drug Discovery
21. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
    Palmer, Suetonia C, Tendal, Britta, Mustafa, Reem A, Vandvik, Per Olav, Li, Sheyu, Hao, Qiukui, Tunnicliffe, David, Ruospo, Marinella, Natale, Patrizia, Saglimbene, Valeria et al. · 2021 · BMJ
22. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure
    Ezekowitz, Justin A., O'Meara, Eileen, McDonald, Michael A., Abrams, Howard, Chan, Michael, Ducharme, Anique, Giannetti, Nadia, Grzeslo, Adam, Hamilton, Peter G., Heckman, George A. et al. · 2017 · Canadian Journal of Cardiology
23. Heart failure
    Marco Metra, John R. Teerlink · 2017 · The Lancet
24. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium
    Packer, Milton · 2018 · Journal of the American College of Cardiology
25. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
    Xi Lu, Qingxing Xie, Xiaohui Pan, Ruining Zhang, Xinyi Zhang, Ge Peng, Yuwei Zhang, Sumin Shen, Nanwei Tong · 2024 · Signal Transduction and Targeted Therapy
26. Heart Failure in Type 2 Diabetes Mellitus
    Helena Kenny, E. Dale Abel · 2019 · Circulation Research
27. The Cardiovascular Biology of Glucagon-like Peptide-1
    Drucker, Daniel J. · 2016 · Cell Metabolism
28. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
    Antonius Baartscheer, Cees A. Schumacher, Rob C. I. Wüst, Jan W.T. Fiolet, Ger J.M. Stienen, Ruben Coronel, Coert Jozef Zuurbier · 2016 · Diabetologia
29. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
    Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, Rodolfo San Antonio, Kiyotake Ishikawa, Shin Watanabe, Belén Picatoste, Eduardo Flores, Álvaro García‐Ropero, Javier Sanz, Roger J. Hajjar et al. · 2019 · Journal of the American College of Cardiology
30. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients
    Angela Velleca, Michael A. Shullo, Kumud K Dhital, Estela Azeka, Monica M Colvin, Eugene Christopher DePasquale, Marta Farrero, Luis Garcı́a-Guereta, Gina Jamero, Kiran K. Khush et al. · 2022 · The Journal of Heart and Lung Transplantation
31. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
    Dunlay, Shannon M., Givertz, Michael M., Aguilar, David, Allen, Larry A., Chan, Michael, Desai, Akshay S., Deswal, Anita, Dickson, Victoria Vaughan, Kosiborod, Mikhail N., Lekavich, Carolyn L. et al. · 2019 · Circulation
32. Type 2 diabetes mellitus in older adults: clinical considerations and management
    Bellary, Srikanth, Kyrou, Ioannis, Brown, James E., Bailey, Clifford J. · 2021 · Nature Reviews Endocrinology
33. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
    Vallon, Volker, Thomson, Scott C. · 2017 · Diabetologia
34. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
    Joseph, Joshua J., Deedwania, Prakash, Acharya, Tushar, Aguilar, David, Bhatt, Deepak L., Chyun, Deborah A., Di Palo, Katherine E., Golden, Sherita H., Sperling, Laurence S., on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension · 2022 · Circulation
35. Mitochondrial dysfunction in diabetic kidney disease
    Josephine Maree Forbes, David R. Thorburn · 2018 · Nature Reviews Nephrology
36. Mechanisms controlling pancreatic islet cell function in insulin secretion
    Jonathan E. Campbell, Christopher B. Newgard · 2021 · Nature Reviews Molecular Cell Biology
37. Calcium Signaling and Reactive Oxygen Species in Mitochondria
    Edoardo Bertero, Christoph Maack · 2018 · Circulation Research
38. The changing face of diabetes complications
    Edward W. Gregg, Naveed A. Sattar, Mohammed Kumail Ali · 2016 · The Lancet Diabetes & Endocrinology
39. Clinical Practice Update on Heart Failure 2019: Pharmacotherapy, Procedures, Devices and Patient Management. An Expert Consensus Meeting Report of the Heart Failure Association of the European Society of Cardiology
    Petar M Seferovic, Piotr P. Ponikowski, Stefan D. Anker, Johann K Bauersachs, Ovidiu Chioncel, John G.F. Cleland, Rudolf A. de Boer, Heinz Drexel, Tuvia Ben Gal, Loreena Hill et al. · 2019 · European Journal of Heart Failure
40. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
    Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A. Schumacher, Jan W.T. Fiolet, Anneke Koeman, Milena Jancev, Markus Werner Hollmann, Nina Claudia Weber, Ruben Coronel et al. · 2017 · Diabetologia
41. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
    Garber, Alan J., Handelsman, Yehuda, Grunberger, George, Einhorn, Daniel, Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bush, Michael A., DeFronzo, Ralph A., Garber, Jeffrey R. et al. · 2020 · Endocrine Practice
42. Diabetes, cardiovascular disease and the microcirculation
    Strain, W. David, Paldánius, P. M. · 2018 · Cardiovascular Diabetology
43. Innate immunity in diabetic kidney disease
    Sydney C.W. Tang, Wai Han Yiu · 2020 · Nature Reviews Nephrology
44. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
    Nauck, Michael A., Meier, Juris J., Cavender, Matthew A., Abd El Aziz, Mirna, Drucker, Daniel J. · 2017 · Circulation
45. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Rao, Sunil V., O’Donoghue, Michelle L., Ruel, Marc, Rab, Tanveer, Tamis-Holland, Jaqueline E., Alexander, John H., Baber, Usman, Baker, Heather, Cohen, Mauricio G., Cruz-Ruiz, Mercedes et al. · 2025 · Circulation
46. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
    Ralph Anthony DeFronzo, William Brian Reeves, Alaa S. Awad · 2021 · Nature Reviews Nephrology
47. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily, Heerspink, Hiddo J L, Cuthbertson, Daniel J, Wilding, John P H · 2021 · The Lancet
48. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children
    Rabi, Doreen M., McBrien, Kerry A., Sapir-Pichhadze, Ruth, Nakhla, Meranda, Ahmed, Sofia B., Dumanski, Sandra M., Butalia, Sonia, Leung, Alexander A., Harris, Kevin C., Cloutier, Lyne et al. · 2020 · Canadian Journal of Cardiology
49. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
    Virani, Salim S., Newby, L. Kristin, Arnold, Suzanne V., Bittner, Vera, Brewer, LaPrincess C., Demeter, Susan Halli, Dixon, Dave L., Fearon, William F., Hess, Beverly, Johnson, Heather M. et al. · 2023 · Journal of the American College of Cardiology
50. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis
    Mudaliar, Sunder, Alloju, Sindura, Henry, Robert R. · 2016 · Diabetes Care
51. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
    Subodh Verma, C. David Mazer, Andrew Tze-Kay Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E. Farkouh, DAVID H. FITCHETT et al. · 2019 · Circulation
52. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
    Derek LeRoith, Geert Jan Biessels, Susan Shapiro Braithwaite, Felipe F. Casanueva, Boris Draznin, Jeffrey B. Halter, Irl B. Hirsch, Marie Elizabeth McDonnell, Mark E. Molitch, Mohammad Hassan Murad et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism
53. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus
    Kato, Eri T., Silverman, Michael G., Mosenzon, Ofri, Zelniker, Thomas A., Cahn, Avivit, Furtado, Remo H.M., Kuder, Julia, Murphy, Sabina A., Bhatt, Deepak L., Leiter, Lawrence A. et al. · 2019 · Circulation
54. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
    Di Pino, Antonino, DeFronzo, Ralph A · 2019 · Endocrine Reviews
55. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
    Sunil V. Rao, Michelle L. O’Donoghue, Marc Ruel, Tanveer Rab, Jaqueline E. Tamis-Holland, John Hunter Alexander, Usman Baber, Heather Baker, Mauricio G. Cohen, Mercedes Cruz-Ruiz et al. · 2025 · Journal of the American College of Cardiology
56. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
    Ralph Anthony DeFronzo, Luke Norton, Muhammad A Abdul‐Ghani · 2016 · Nature Reviews Nephrology
57. Glucagon-like peptide 1 in health and disease
    Andersen, Andreas, Lund, Asger, Knop, Filip K., Vilsbøll, Tina · 2018 · Nature Reviews Endocrinology
58. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
    Petrie, Mark C., Verma, Subodh, Docherty, Kieran F., Inzucchi, Silvio E., Anand, Inder, Belohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K., de Boer, Rudolf A. et al. · 2020 · JAMA
59. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
    Zhou, Hao, Wang, Shuyi, Zhu, Pingjun, Hu, Shunying, Chen, Yundai, Ren, Jun · 2018 · Redox Biology
60. Japanese clinical practice guideline for diabetes 2019
    Araki, Eiichi, Goto, Atsushi, Kondo, Tatsuya, Noda, Mitsuhiko, Noto, Hiroshi, Origasa, Hideki, Osawa, Haruhiko, Taguchi, Akihiko, Tanizawa, Yukio, Tobe, Kazuyuki et al. · 2020 · Diabetology International
61. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
    Frank L.J. Visseren, François Mach, Yvo Michiel Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Bénétos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno et al. · 2021 · European Journal of Preventive Cardiology
62. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
    So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee et al. · 2020 · Nature Communications
63. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
    Carlos G. Santos‐Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibáñez, Álvaro García‐Ropero, DONNA M. MANCINI, Sean Pinney, Frank Macaluso, Samantha Sartori, Mercè Roqué, Fernando Sabatel-Pérez et al. · 2020 · Journal of the American College of Cardiology
64. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
    Iglay, Kristy, Hannachi, Hakima, Joseph Howie, Patrick, Xu, Jinfei, Li, Xueying, Engel, Samuel S., Moore, Lori M., Rajpathak, Swapnil · 2016 · Current Medical Research and Opinion
65. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
    Roni Ranghoej Nielsen, Niels Møller, Lars Christian Gormsen, Lars Poulsen Tolbod, Nils Henrik Hansson, Jens Sorensen, Hendrik Johannes Harms, Jørgen Frøkiær, Hans Eiskjær, Nichlas Riise Jespersen et al. · 2019 · Circulation
66. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication
    Joakim Nordanstig, Christian‐Alexander Behrendt, Iris Baumgärtner, J. J. F. Belch, Maria Bäck, Robert Fitridge, Robert J. Hinchliffe, Anne Lejay, Joseph L. Mills, Ulrich Rother et al. · 2023 · European Journal of Vascular and Endovascular Surgery
67. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
    Volker Vallon, Subodh Verma · 2020 · Annual Review of Physiology
68. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
    Hsia, Daniel S., Grove, Owen, Cefalu, William T. · 2017 · Current Opinion in Endocrinology, Diabetes &amp; Obesity
69. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
    Mahaffey, Kenneth W., Neal, Bruce, Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Fabbrini, Elisa, Sun, Tao, Li, Qiang et al. · 2018 · Circulation
70. The role of adipose tissue in cardiovascular health and disease
    Evangelos K. Oikonomou, Charalambos A. Antoniades · 2018 · Nature Reviews Cardiology
71. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
    Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel E. Dagogo-Jack, Ralph A. DeFronzo, DANIEL F. EINHORN, Vivian Andrew Fonseca et al. · 2018 · Endocrine Practice
72. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
    Blonde, Lawrence, Umpierrez, Guillermo E., Reddy, S. Sethu, McGill, Janet B., Berga, Sarah L., Bush, Michael, Chandrasekaran, Suchitra, DeFronzo, Ralph A., Einhorn, Daniel, Galindo, Rodolfo J. et al. · 2022 · Endocrine Practice
73. Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis
    Hallow, Karen M., Helmlinger, Gabriel, Greasley, Peter J., McMurray, John J. V., Boulton, David W. · 2018 · Diabetes, Obesity and Metabolism
74. From pre-diabetes to diabetes: diagnosis, treatments and translational research
    Khan, Radia, Chua, Zoey, Tan, Jia, Yang, Yingying, Liao, Zehuan, Zhao, Yan · 2019 · Medicina
75. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
    Rådholm, Karin, Figtree, Gemma, Perkovic, Vlado, Solomon, Scott D., Mahaffey, Kenneth W., de Zeeuw, Dick, Fulcher, Greg, Barrett, Terrance D., Shaw, Wayne, Desai, Mehul et al. · 2018 · Circulation
76. Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
    Francesco Zaccardi, David R. Webb, Zin Zin Htike, Dina Ahmed Hosney Youssef, Kamlesh Khunti, Melanie Jane Davies · 2016 · Diabetes Obesity and Metabolism
77. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2020</i>
    American Diabetes Association · 2020 · Diabetes Care
78. 2016 European Guidelines on cardiovascular disease prevention in clinical practice
    Massimo Francesco Piepoli, Arno Wilhelmus Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, Alberico Luigi Catapano, Marie Therese Cooney, Ugo Corrà, Bernard Cosyns, Christi Deaton et al. · 2016 · Atherosclerosis
79. 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
    2017 · Diabetes Care
80. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
    Iain C. Macdougall, Andreas J. Bircher, Kai‐Uwe Eckardt, Gregorio T. Obrador, Carol A. Pollock, Peter Stenvinkel, Dorine W. Swinkels, Christoph Wanner, Günter Weiß, Glenn Matthew Chertow et al. · 2016 · Kidney International
81. 10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes—2023</i>
    ElSayed, Nuha A., Aleppo, Grazia, Aroda, Vanita R., Bannuru, Raveendhara R., Brown, Florence M., Bruemmer, Dennis, Collins, Billy S., Das, Sandeep R., Hilliard, Marisa E., Isaacs, Diana et al. · 2023 · Diabetes Care
82. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
    Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Januzzi, James L., Kalyani, Rita R., Kosiborod, Mikhail, Magwire, Melissa, Morris, Pamela B., Neumiller, Joshua J. et al. · 2020 · Journal of the American College of Cardiology
83. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease
    Wanner, Christoph, Lachin, John M., Inzucchi, Silvio E., Fitchett, David, Mattheus, Michaela, George, Jyothis, Woerle, Hans J., Broedl, Uli C., von Eynatten, Maximilian, Zinman, Bernard · 2018 · Circulation
84. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
    Jason H. Y. Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Charles Neal · 2016 · The Lancet Diabetes & Endocrinology
85. 10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2019</i>
    American Diabetes Association · 2019 · Diabetes Care
86. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature
    Jack Stewart, Gavin Paul Raphael Manmathan, Peter Wilkinson · 2017 · JRSM Cardiovascular Disease
87. The tubular hypothesis of nephron filtration and diabetic kidney disease
    Vallon, Volker, Thomson, Scott C. · 2020 · Nature Reviews Nephrology
88. Post-Myocardial Infarction Heart Failure
    Maria Cecilia Bahit, Ajar Kochar, Christopher Bull Granger · 2018 · JACC Heart Failure
89. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
    Rodbard, Helena W., Rosenstock, Julio, Canani, Luis H., Deerochanawong, Chaicharn, Gumprecht, Janusz, Lindberg, Søren Østergaard, Lingvay, Ildiko, Søndergaard, Anette Luther, Treppendahl, Marianne Bach, Montanya, Eduard et al. · 2019 · Diabetes Care
90. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
    Ma, Cheng-Xu, Ma, Xiao-Ni, Guan, Cong-Hui, Li, Ying-Dong, Mauricio, Dídac, Fu, Song-Bo · 2022 · Cardiovascular Diabetology
91. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk
    Chia, Chee W., Egan, Josephine M., Ferrucci, Luigi · 2018 · Circulation Research
92. The impact of insulin resistance on the kidney and vasculature
    Ferruh Artunç, Erwin D. Schleicher, Cora Weigert, Andreas Fritsche, Norbert Stefan, Hans‐Ulrich Häring · 2016 · Nature Reviews Nephrology
93. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
    Mikhail Kosiborod, Carolyn S.P. Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan E. Shaw, Navdeep Tangri, Su‐Yen Goh, Marcus Thuresson, Hungta Chen et al. · 2018 · Journal of the American College of Cardiology
94. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
    Yuliya Lytvyn, Petter Bjornstad, Jacob Allen Udell, Julie A. Lovshin, David Z.I. Cherney · 2017 · Circulation
95. Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
    Kevin Damman, Joost C. Beusekamp, Eva M. Boorsma, Henk P. Swart, Tom D.J. Smilde, Arif Elvan, J.W. Martijn van Eck, Hiddo J.L. Heerspink, Adriaan A. Voors · 2020 · European Journal of Heart Failure
96. 8. Pharmacologic Approaches to Glycemic Treatment
    American Diabetes Association · 2016 · Diabetes Care
97. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
    Andrew A. House, Christoph Wanner, Mark J. Sarnak, Ileana L. Piña, Christopher William McIntyre, Paul V. J. Komenda, B.L. Kasiske, Anita M Deswal, Christopher R. deFilippi, John G.F. Cleland et al. · 2019 · Kidney International
98. Loss of Metabolic Flexibility in the Failing Heart
    Qutuba G. Karwi, Golam Mezbah Uddin, Kim L. Ho, Gary D. Lopaschuk · 2018 · Frontiers in Cardiovascular Medicine
99. American D iabetes A ssociation S tandards of M edical C are in D iabetes 2017
    Payal H. Marathe, Helen X. Gao, Kelly L. Close · 2017 · Journal of Diabetes
100. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary
     Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2017 · Endocrine Practice